Amarin Corporation PLC (AMRN.OQ)
11 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|67||2014||Independent Chairman of the Board|
|56||2014||President, Chief Executive Officer, Assistant Secretary, Director|
|45||2016||Chief Financial Officer, Senior Vice President|
|50||2016||President - Research and Development, Senior Vice President, Chief Scientific Officer|
|47||2012||Senior Vice President, Chief Compliance Officer, General Counsel, Secretary|
- BRIEF-Amarin reports Q3 loss per share $0.04
- BRIEF-Amarin and HLS Therapeutics announce agreement to commercialize Vascepa in Canada
- BRIEF-Amarin names Mark Salyer chief commercial officer
- BRIEF-Amarin's reduce-it cardiovascular outcomes study of Vascepa to continue as planned
- BRIEF-Amarin reports Q2 loss per share $0.05